TVRD Latest Press Releases

-- July 30, 2026 --

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109 Globe Newswire 7:30 AM

-- July 7, 2026 --

Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement Globe Newswire 7:00 AM

-- May 21, 2026 --

Tvardi Therapeutics to Participate in Upcoming Investor Events Globe Newswire 8:00 AM

-- May 8, 2026 --

Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update Globe Newswire 7:00 AM

-- April 2, 2026 --

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium Globe Newswire 8:00 AM

-- March 31, 2026 --

Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update Globe Newswire 4:01 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software